TriangleHEALTH PROFESSIONAL · SOURCE READING
Induction Therapy
Source: Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Childhood AML
Contemporary pediatric AML protocols result in 85% to 90% complete remission (CR) rates.[1-3] To achieve a CR, inducing profound bone marrow aplasia (with the exception of the M3 APL subtype) is usually necessary with currently used combination-chemotherapy regimens. Because induction chemotherapy produces severe myelosuppression, morbidity and mortality from infection or hemorrhage during the induction period may be significant. Approximately 2% to 3% of patients die during the induction phase, most often caused by treatment-related complications.[1-4]
Treatment options for children with AML during the induction phase may include the following:
Chemotherapy.
Source links and citations
Immunotherapeutic approaches (e.g., gemtuzumab ozogamicin).
Source links and citations
Targeted therapy (e.g., FLT3 inhibitors).
Source links and citations
Supportive care.
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice